

CONFIDENCE: Real-world effectiveness of ocrelizumab in relapsing MS over

18 months (82 of 83 characters)

Short title: Real-world effectiveness of Ocrelizumab (40 of 45 characters)

Buttmann M,¹ Meuth SG,² Weber MS,³ Dirks P,⁴ Eggebrecht JC,⁵ Hieke-Schulz S,⁵ Leemhuis J,⁵ Ziemssen T⁶

¹Caritas Krankenhaus, Bad Mergentheim, Germany; ²Department of Neurology, University Clinic Düsseldorf, Heinrich-Heine-University Düsseldorf, Germany; ³Institute of Neuropathology, Department of Neurology, University Medicine Göttingen, Germany; ⁴F. Hoffmann – La Roche AG, Basel, Switzerland, ⁵Roche Pharma AG, Grenzach-Wyhlen, Germany; ⁶Center of Clinical Neuroscience, Neurological Clinic, Carl Gustav Carus University Clinic, University of Technology, Dresden, Germany

Background:

As of December 2020, >200,000 patients with relapsing (RMS) or primary progressive multiple sclerosis (PPMS) have initiated treatment with ocrelizumab (OCR), a humanized anti-CD20 antibody.

Objective:

To analyze the effectiveness of OCR in patients with RMS, treatment-naïve (TN) patients and patients with prior MS-specific therapies (PMST), over 18 months. These data were originally presented at the 37th Congress of theECTRIMS, October 13–15, 2021.

Methods:

CONFIDENCE (ML39632, EUPAS22951) is an ongoing non-interventional study aiming to enroll 3,000 patients newly treated with OCR and 1,500 patients newly treated with other selected disease-modifying therapies in Germany, with 7.5–10 years follow-up. OCR-treated RMS patients with ≥1 post-initiation assessment visit were analyzed for relapses and change in Expanded Disability Status Scale (EDSS) over time (datacut 14/10/2020).

Results:

In this interim analysis, 1,510 OCR-treated patients with RMS were included. Average age, mean duration since the first MS symptoms and baseline EDSS tended to increase with the number of PMST. In the OCR-treated RMS population with at least 18 months of follow-up, the mean change (SD) in EDSS was 0.06 (0.74; n=477). Patients with ≥3 PMST had a comparable EDSS change (0.08 [0.71; n=187]), while TN patients had a slight decrease in EDSS (–0.03 [0.93; n=64]). In the OCR-treated RMS population, the proportion of relapse-free patients was 88.90% within 6 months, 93.26% within 6–12 months and 95.18% within 12–18 months. The proportions of relapse-free TN vs ≥3 PMST patients were 91.82% vs

85.08% within 6 months, 99.32% vs 90.84% within 6–12 months and 97.80% vs 93.86% within 12–18 months, respectively.

Conclusions:

Over 18 months, patients treated at an early line with OCR retained a low mean baseline EDSS. The vast majority of OCR-treated patients with RMS in CONFIDENCE remained relapse-free, with the highest proportion in the TN population.

Word count: 300 (300 max)

Submission subgroup: Clinical

Disclosures:

- **M Buttman** received honoraria for lecturing, consulting and/or travel expenses for attending meetings from Bayer, Biogen, Boehringer, Celgene, Coloplast, Daiichi-Sankyo, Das Fortbildungskolleg, Merck, Novartis, Roche, Sanofi and Teva
- **SG Meuth** receives honoraria for lecturing, and travel expenses for attending meetings from Almirall, Amicus Therapeutics Germany, Bayer Health Care, Biogen, Celgene, Diamed, Genzyme, MedDay Pharmaceuticals, Merck Serono, Novartis, Novo Nordisk, ONO Pharma, Roche, Sanofi-Aventis, Chugai Pharma, QuintilesIMS and Teva. His research is funded by the German Ministry for Education and Research (BMBF), Bundesinstitut für Risikobewertung (BfR), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Gemeinsamer Bundesausschuss (G-BA), German Academic Exchange Service, Hertie Foundation, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, German Foundation Neurology and Alexion, Almirall, Amicus Therapeutics Germany, Biogen, Diamed, Fresenius Medical Care, Genzyme, HERZ Burgdorf, Merck Serono, Novartis, ONO Pharma, Roche, and Teva.
- **MS Weber** receives research support from the Deutsche Forschungsgemeinschaft (DFG; WE 3547/5-1), from Novartis, TEVA, Biogen-Idec, Roche, Merck and the ProFutura Programm of the Universitätsmedizin Göttingen. M.S.W. is serving as an editor for PLoS One. He received travel funding and/or speaker honoraria from Biogen-Idec, Merck Serono, Novartis, Roche, TEVA, Bayer and Genzyme
- **P Dirks** is an employee of F. Hoffmann-La Roche AG and shareholder of F. Hoffmann-La Roche AG.
- **JC Eggebrecht** is an employee of Roche Pharma AG and shareholder of F. Hoffmann-La Roche AG
- **S Hieke-Schulz** is an employee of Roche Pharma AG.
- **J Leemhuis** is an employee of Roche Pharma AG and shareholder of F. Hoffmann-La Roche AG.
- **T Ziemssen** reports grants and personal fees from Biogen, Roche, Merck, TEVA, and Almirall; grants, personal fees and non-financial support from Genzyme and Novartis; and personal fees from Bayer, BAT, Celgene and Gilead.